Ex-HGS director draws fire for plugging anthrax drug at Pentagon

Did Human Genome Sciences unfairly benefit from its political connections? According to a Los Angeles Times investigation, former Navy Secretary Richard Danzig talked up HGS' anthrax drug raxibacumab to his government contacts--at a time when he also served on the company's board. HGS scored some $334 million worth of government contracts for raxibacumab, which was its sole marketed product for years. The government remains the drug's only buyer, the Times says. Report

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…